Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;32(6):609-616.
doi: 10.1097/BOR.0000000000000754.

Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis

Sonali Narain  1 , Nicola Berman, Richard Furie
Affiliations
Review

Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis

Sonali Narain et al. Curr Opin Rheumatol. 2020 Nov.

Abstract

Purpose of review: It is an understatement to say that drug approvals in systemic lupus erythematosus (SLE), lupus nephritis, and Sjogren's syndrome have lagged far behind those in other autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis. Reasons for this are multiple and include the molecular and clinical heterogeneity of these conditions; confounding by background medications, especially corticosteroids; and clinical trial endpoints. However, the tides are changing, and there have been several bright spots in our attempts to bring more efficacious drugs to our patients.

Recent findings: Several positive phase II and phase III trials in SLE and lupus nephritis with drugs such as anifrolumab, voclosporin, belimumab, and obinutuzumab will no doubt eventually generate regulatory approvals for most, if not all, of these drugs. Although early in development, the promising results in Sjogren's syndrome with iscalimab and ianalumab should make the Sjogren's syndrome community quite hopeful of future drug approvals.

Summary: In this review, we highlight recent study results in Sjogren's syndrome, SLE, and lupus nephritis, emphasizing investigational therapies in late stage development, but we also provide a glimpse into drugs of the future.

PubMed Disclaimer

References

    1. Furie R, Aroca G, Alvarez A, et al. A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis [abstract]. Arthritis Rheumatol 2019; 71: (Suppl 10): https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-pla.... [Accessed September 8, 2020].
    1. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721–731.
    1. Mavragani CP, Moutsopoulos HM. Sjogren's syndrome: old and new therapeutic targets. J Autoimmun 2020; 110:102364.
    1. Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome. Arthritis Rheumatol 2017; 69:1440–1450.
    1. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015; 74:526–531.

MeSH terms

Substances